Depressor effect of intraventricular administration of calcium on spontaneously hypertensive rats.
The role of central Ca2+ in the regulation of blood pressure (BP) was investigated in conscious spontaneously hypertensive (SHR) and Wistar-Kyoto rats (WKY). Ten microliters of a high Ca2+ solution (Ca2+: 32.6 mM) administered intracerebroventricularly (i.c.v.) decreased the mean arterial pressure (MAP) for more than 20 min in SHR (n = 7, P < 0.005), while no change of MAP was observed in the WKY (n = 6). This depressor response to Ca2+ i.c.v. was dose-dependent at Ca2+ concentrations between 16.3 and 65.2 mM. We also investigated the effect of high Ca2+ i.c.v. in SHR after pretreatment with Ca2+ channel blockers, diltiazem (60 micrograms/10 microliters) or nisoldipine (4, 8, 16 and 32 micrograms/10 microliters), administered i.c.v., the autonomic ganglion blocker, hexamethonium (50 mg/kg), administered i.v. and alpha-methyl-p-tyrosine (100 and 400 micrograms/10 microliters) delivered i.c.v. Pretreatment with i.c.v. diltiazem (n = 8) or nisoldipine (n = 5 for 8 micrograms, n = 6 for 4, 16, 32 micrograms) abolished and/or blunted the decrease of MAP due to high Ca2+. Hexamethonium administered i.v. (n = 6) also canceled the depressor action of i.c.v. Ca2+. Pretreatment with 100 micrograms of i.c.v. alpha-methyl-p-tyrosine could not prevent the depressor action of i.c.v. Ca2+; however, 400 micrograms of alpha-methyl-p-tyrosine administered i.c.v. abolished the effect of i.c.v. Ca2+. Furthermore Ca2+ channel blockers administered i.c.v. in themselves increased MAP in SHR (P < 0.05). These results suggest that central Ca2+ is involved in the central regulation of BP in SHR. This effect may be mediated through changes in sympathetic activity.
Kusano
S
S
Third Department of Internal Medicine, Nagasaki University School of Medicine, Japan.
Seto
S
S
Akahoshi
M
M
Kitamura
S
S
Nagao
S
S
Ozeki
S
S
Yano
K
K
Hashiba
K
K
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D002118:Calcium / Q000008:administration & dosage*; D015220:Calcium Channels / Q000187:drug effects; D005730:Ganglionic Blockers / Q000494:pharmacology; D018738:Hexamethonium; D006584:Hexamethonium Compounds / Q000494:pharmacology; D007276:Injections, Intraventricular; D008297:Male; D008781:Methyltyrosines / Q000494:pharmacology; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D012016:Reference Values; D013564:Sympathetic Nervous System / Q000502:physiology; D019805:alpha-Methyltyrosine
D015220:Calcium Channels; D005730:Ganglionic Blockers; D006584:Hexamethonium Compounds; D008781:Methyltyrosines; D018738:Hexamethonium; D019805:alpha-Methyltyrosine; D002118:Calcium